Building a Business Case for Biopharmaceutical QbD Implementation (Peer Reviewed) - The author describes a methodology for developing a per product qualitative and semi-qualitative business case for a

ADVERTISEMENT

Building a Business Case for Biopharmaceutical QbD Implementation (Peer Reviewed)
The author describes a methodology for developing a per product qualitative and semi-qualitative business case for applying QbD to a biopharmaceutical product.


BioPharm International
Volume 25, Issue 8, pp. 40-47

21. J. Catania, BioPharm Int. 24 (3), 20–24 (2011).

22. J. Catania, Biopharm Int. 24 (5), 20–24 (2011).

23. A. Sinclair and M. Monge, Bioprocess Int. 8 (3), 16–18 (2010).

24. T. Fuhr, State of QbD Implementation: Adoption, Successes, and Challenges (McKinsey 2010).

25. T. Fuhr and K. George, Pharmaceutical Manufacturing, 10 (3), 43–45 (2011).

26. T. Fuhr and K. George, "Moving Beyond the Business Case for QbD," March 13, 2011, http://www.pharmaqbd.com/mckinsey_beyond_business_case_qbd/, accessed Jul. 17, 2012.

27. P. Thomas, 2010, "QbD works: Detailing the Value Prop at Pfizer," http://www.pharmaqbd.com/?s=Qbd+works%3A+detailing+the+value+prop+at+pfizer, accessed Jul. 17, 2012.

28. B.K. Nunnally and J.S. McConnell, Six Sigma in the Pharmaceutical Industry (CRC Press, Boca Raton, FL, 2007) pp. 83–92.

29. B. Junker et al., PDA J. Pharm. Sci. Technol. 65 (3), 254–286 (2011).

30. "Woodcock Holds Court: Notes from a Lively CDER Town Hall," Pharma QbD, Jun. 21, 2010, http://www.pharmaqbd.com/woodcock_holds_court_town_hall/, accessed Jul. 17, 2012.

31. A. Shanley, Pharmaceutical Manufacturing 10 (2), 7 (2011).

32. FDA, Manual of Policies and Procedures, 5016.1: Applying ICH Q8(R2), Q9, and Q10 Principles to CMC Review, Feb. 28, 2011, http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/UCM242665.pdf, accessed Jul. 17, 2012.

33. FDA, Guidance for Industry: Process Validation: General Prinicples and Practices (Rockville, MD, Jan. 2011).

34. D. Stevenson and T. Cochrane, Regulatory Rapporteur, 8 (3), 18–20 (2011).

35. J. Wechsler, BioPharm Int. 24 (7), 12–14 (2011).

36. J. Avellanet, Pharmaceutical Manufacturing, 10 (5), 10 (2011).

37. S.M. Paul et al., Nat. Rev. Drug. Discov. 9, 203–214 (2010).

38. N. Subbaraman, Nat. Biotechnol. 29 (5), 381 (2011).

39. J.A. DiMasi, and H.G. Grabowski, Managerial and Decision Economics 28, 469–479 (2007).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here